Corvus Pharmaceuticals (CRVS) CBO receives 100,000 stock options

Rhea-AI Filing Summary

Corvus Pharmaceuticals reported that its Chief Business Officer, Jeffrey Arcara, acquired a stock option covering 100,000 shares of common stock on December 4, 2025. The option has an exercise price of $8.81 per share and is held directly.

The underlying shares vest in equal monthly installments, with 1/36 of the shares vesting each month starting from December 4, 2025, as long as Arcara continues his service with the company. The option expires on December 4, 2035, and following this transaction he beneficially owned 100,000 stock options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Arcara Jeffrey

(Last) (First) (Middle)

C/O CORVUS PHARMACEUTICALS, INC.

901 GATEWAY BOULEVARD, THIRD FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Corvus Pharmaceuticals, Inc. [ CRVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.81	12/04/2025		A		100,000		(1)	12/04/2035	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

	/s/ Leiv Lea, as Attorney-in-Fact for Jeffrey Arcara	12/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Corvus Pharmaceuticals (CRVS) disclose in this filing?

Corvus Pharmaceuticals disclosed that Chief Business Officer Jeffrey Arcara acquired a stock option for 100,000 shares of common stock on December 4, 2025, with an exercise price of $8.81 per share.

What are the vesting terms of Jeffrey Arcara’s 100,000 Corvus Pharmaceuticals (CRVS) stock options?

The filing states that the shares underlying the option vest and become exercisable as to 1/36 of the shares in successive, equal monthly installments measured from December 4, 2025, subject to Arcara’s continued service relationship with the company on each vesting date.

When do Jeffrey Arcara’s Corvus Pharmaceuticals (CRVS) stock options expire?

The stock option reported in the filing expires on December 4, 2035, giving a ten-year term from the transaction date of December 4, 2025.

What is the exercise price of the Corvus Pharmaceuticals (CRVS) stock options reported?

The stock option has a conversion or exercise price of $8.81 per share for the underlying Corvus Pharmaceuticals common stock.

How many Corvus Pharmaceuticals (CRVS) derivative securities does Jeffrey Arcara own after this transaction?

After the reported transaction, Jeffrey Arcara beneficially owned 100,000 derivative securities (stock options), all held with direct ownership.

What is Jeffrey Arcara’s role at Corvus Pharmaceuticals (CRVS) according to this filing?

According to the filing, Jeffrey Arcara is an officer of Corvus Pharmaceuticals, serving as its Chief Business Officer.